Dynamic immunoediting of tumours may hold the clue to effective treatment with immunotherapy
Success of immunotherapy is tied to tumour evolution from early- to late-stages, as a study in non-small-cell lung cancer highlights
Molecular cancer early detection and prevention - an attainable goal?
Adoption of molecular-based early detection techniques in clinical practice depends on the success of large-scale clinical studies and cost barriers
Antibody–drug conjugates show potential in advanced solid tumours
Study data report promising responses and safety profiles in patients with heavily pre-treated malignancies
Can new routes of administration have a place in the application of immunotherapy?
Immunotherapy typically requires intravenous administration, but this may not be the optimal or preferred route for all patients
New therapies, new toxicities
Side-effects may occur at unpredictable timepoints during a patient’s treatment journey and even after treatment cessation
Adjuvant immunotherapy does not improve disease-free survival in renal cell carcinoma
IMmotion010, CheckMate 914 and PROSPER miss their primary endpoints: back to square one for adjuvant immunotherapy?
Neoadjuvant or adjuvant immunotherapy – which is the best approach?
The role of neoadjuvant versus adjuvant immunotherapy is no simple comparison but instead involves a complex interplay of factors, based on tumour immune responsiveness, immunotherapy type, combination partners and trial design
Liquid biopsy moving to early cancer detection: is it still early times?
Despite the promises shown by some innovative technologies in the studies presented, they will not replace existing diagnostic modalities soon
New FGFR inhibitors show potential for the treatment of cholangiocarcinoma
Two early studies investigate the anticancer activity of derazantinib and RLY-4008 in patients with FGFR inhibitor-naïve cholangiocarcinoma
Has TIL therapy the potential to change cancer treatment?
After TILs have shown benefits in advanced melanoma, many ‘synthetic biology’ strategies can be conceived to potentially extend this clinical signal to other patient groups